[Cusabio] TNFRSF17, An Emerging Therapeutic Target for CAR-T
작성자
abbabio
작성일자
2019-07-19
조회수
546
If you are unable to see the message below, click here to view
TNFRSF17 also know as B-Cell Maturation Antigen(BCMA) or CD269. It is a member of the TNF-receptor family. It is mainly expressed on the surface of mature B cells and plasmocyte, and plays an important role in the maturation and autoimmune response of B cells.
Binding of BCMA to ligand can activate a series of intracellular signaling pathways such as p38 and Elk, which play an important role in both autoimmune diseases and humoral immunity. Therefore, BCMA may be related to many diseases.
Its importance makes it a target for immunotherapy, particularly for the treatment of multiple myeloma.
CUSABIO provides an TNFRSF17 protein with high purity and activity validated.
The Show of Product
Product Name: Recombinant Human Tumor necrosis factor receptor superfamily member 17(TNFRSF17),partial
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Protein purity is greater than 90% as determined by SDS-PAGE.
Activity
Measured by its binding ability in a functional ELISA. Immobilized BCMA at 2 μg/ml can bind human BCMA antibody, the EC50 of human BCMA protein is 1.912-2.488 ng/ml.
Currently, novel tumor immunotherapy methods for BCMA mainly include Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T), Bispecific antibody (BsAb) and Antibody-drug coupling (ADC). Recent studies have also shown that CAR-T targeting BCMA is effective in clearing myeloma cells in vivo.
For additional information about TNFRSF17, such as TNFRSF17 structure, tissue specificity, function, its relationship to disease, its application in treatment, etc., please refer to the article: Focus on Emerging Therapeutic Targets BCMA.
